natgillin/translations-raw huggingface dataset:
Reproduction is authorised provided the source is acknowledged. person is given the vaccine, the immune system recognises the virus as ‘foreign’ and makes antibodies against it.
Reproduction is authorised provided the source is acknowledged. uppfattar immunsystemet det som främmande och bildar antikroppar mot det.
Reproduction is authorised provided the source is acknowledged. polymerase, which is used to produce the RNA that the bacteria need to make proteins.
Reproduction is authorised provided the source is acknowledged. rna-polymeras, som används för att producera det rna som bakterierna behöver för att bilda proteiner.
Reproduction is authorised provided the source is acknowledged. pressure is not reached, the dose can be increased to 80 mg, or another medicine for hypertension can be added, such as hydrochlorothiazide.
Om målblodtrycket inte uppnås kan dosen ökas till 80 mg eller också kan ett annat läkemedel mot högt blodtryck läggas till, exempelvis hydroklorotiazid.
Reproduction is authorised provided the source is acknowledged. primary generalised tonic-clonic seizures (major fits, including loss of consciousness) in patients from 12 years of age with idiopathic generalised epilepsy (the type of epilepsy that is thought to be inherited).
Reproduction is authorised provided the source is acknowledged. primära generaliserade tonisk-kloniska anfall (större anfall, inklusive medvetandeförlust) hos patienter från 12 års ålder med idiopatisk generaliserad epilepsi (den typ av epilepsi som antas vara ärftlig).
Reproduction is authorised provided the source is acknowledged. primary generalised tonic-clonic seizures (major fits, including loss of consciousness) in patients from 12 years of age with idiopathic generalised epilepsy (the type of epilepsy that is thought to have a genetic cause).
Reproduction is authorised provided the source is acknowledged. primära generaliserade tonisk-kloniska anfall (större anfall, inklusive medvetandeförlust) hos patienter från 12 års ålder med idiopatisk generaliserad epilepsi (den typ av epilepsi som antas vara ärftlig).
Reproduction is authorised provided the source is acknowledged. problems treatment should be interrupted.
Reproduction is authorised provided the source is acknowledged. kontrolleras innan behandlingen inleds och regelbundet därefter.
Reproduction is authorised provided the source is acknowledged. progression and survival rates as the patients taking tamoxifen.
Reproduction is authorised provided the source is acknowledged. till progression och överlevnad som de patienter som fick tamoxifen.
Reproduction is authorised provided the source is acknowledged. prostaglandins are substances that trigger inflammation, pain, exudation and fever, meloxicam reduces those responses.
Reproduction is authorised provided the source is acknowledged. ämnen som utlöser inflammation, smärta, exsudation (vätskeutsöndring) och feber och meloxikam minskar dessa reaktioner.
Reproduction is authorised provided the source is acknowledged. protein called ‘SMO’, which is involved in activating the Hedgehog signalling pathway.
Reproduction is authorised provided the source is acknowledged. involverat i aktiveringen av Hedgehog-signalvägen.
Reproduction is authorised provided the source is acknowledged. reached, the dose can be increased to 80 mg, or another medicine for hypertension can be added, such as hydrochlorothiazide.
Reproduction is authorised provided the source is acknowledged. målblodtrycket inte uppnås kan dosen ökas till 80 mg eller också kan ett annat läkemedel mot högt blodtryck läggas till, exempelvis hydroklortiazid.
Reproduction is authorised provided the source is acknowledged. reduces the numbers of eosinophils.
Reproduction is authorised provided the source is acknowledged. minskar därigenom antalet eosinofiler.
Reproduction is authorised provided the source is acknowledged. released more slowly from the capsule than it is in Prograf/Prograft.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. rumen resulting in an increase of the bacteria that produce propionate, a substance used to make glucose.
Reproduction is authorised provided the source is acknowledged. ett ämne som används för att tillverka glukos.
Reproduction is authorised provided the source is acknowledged. same time as the first infusion.
Reproduction is authorised provided the source is acknowledged. tid som den första infusionen.
Reproduction is authorised provided the source is acknowledged. same way as human factor VIII.
Reproduction is authorised provided the source is acknowledged. verkar i kroppen på samma sätt som human faktor VIII.
Reproduction is authorised provided the source is acknowledged. septicaemia (bacteria present in blood) and toxaemia (a toxic state) (mastitis-metritis-agalactia syndrome).
Reproduction is authorised provided the source is acknowledged. behandla sjukdomar som uppkommer efter grisning (födsel av kultingar) t.ex. dräktighetsförgiftning (bakterier i blodet) och toxemi (ett toxiskt tillstånd) (mastit-metrit-agalakti-syndrom).
Reproduction is authorised provided the source is acknowledged. similar ways to reduce blood pressure by allowing the blood vessels to relax.
Reproduction is authorised provided the source is acknowledged. och sänker blodtrycket genom att de får blodkärlen att slappna av.
Reproduction is authorised provided the source is acknowledged. six hours or extend the monitoring period if needed.
Reproduction is authorised provided the source is acknowledged. timmar.
Reproduction is authorised provided the source is acknowledged. slow injection under the skin) in an area such as the abdomen (belly), thigh, upper arm or hip.
Reproduction is authorised provided the source is acknowledged. eller höft.
Reproduction is authorised provided the source is acknowledged. stimulates the growth and activity of eosinophils.
Reproduction is authorised provided the source is acknowledged. stimulerar eosinofilernas tillväxt och aktivitet.
Reproduction is authorised provided the source is acknowledged. stimulation, cGMP is produced in the penis, where it causes the muscle in the spongy tissue of the penis (the corpora cavernosa) to relax.
Reproduction is authorised provided the source is acknowledged. produceras cGMP i penis, där det får muskeln i dess svampvävnad (svällkroppen) att slappna av.
Reproduction is authorised provided the source is acknowledged. strength that continues to provide the same doses.
Reproduction is authorised provided the source is acknowledged. doser.
Reproduction is authorised provided the source is acknowledged. study involving 285 patients.
Reproduction is authorised provided the source is acknowledged. jämförts med tilläggsbehandling med placebo (overksamma ögondroppar) i en studie där 285 patienter ingick.
Reproduction is authorised provided the source is acknowledged. substance which increases electrical activity in the brain.
Reproduction is authorised provided the source is acknowledged. blockerar även receptorer för glutamat, ett ämne som bidrar till ökad elektrisk aktivitet i hjärnan.
Reproduction is authorised provided the source is acknowledged. susoctocog alfa, works in the body in the same way as human factor VIII, but has a slightly different shape.
Reproduction is authorised provided the source is acknowledged. annorlunda form.
Reproduction is authorised provided the source is acknowledged. tablets with food and take the first tablet of an increased dose in the evening rather than the morning.
Reproduction is authorised provided the source is acknowledged. bättre om de tar sina tabletter tillsammans med mat och tar den första tabletten med ökad dos på kvällen i stället för på morgonen.
Reproduction is authorised provided the source is acknowledged. tenofovir, or need to take different doses, they will need to take medicines containing emtricitabine or tenofovir disoproxil separately.
Reproduction is authorised provided the source is acknowledged. emtricitabin eller tenofovir, eller behöver ta en annan dos, måste de ta läkemedel som innehåller emtricitabin eller tenofovirdisoproxil separat.
Reproduction is authorised provided the source is acknowledged. than three times the normal level).
Reproduction is authorised provided the source is acknowledged. inledas eller så ska den avbrytas.
Reproduction is authorised provided the source is acknowledged. that fights infection) and platelets (components that help the blood to clot), the dose may have to be reduced or treatment may have to be delayed.
Reproduction is authorised provided the source is acknowledged. infektioner) och trombocyter (komponenter som hjälper blodet att koagulera) kan det bli nödvändigt att minska dosen eller fördröja behandlingen.
Reproduction is authorised provided the source is acknowledged. the body’s hormonal balance to prevent ovulation, by altering the cervical mucus and by thinning the endometrium (the lining of the womb).
Reproduction is authorised provided the source is acknowledged. hormonbalans så att ägglossning förhindras, genom att förändra livmoderhalssekretet och förtunna livmoderslemhinnan (livmoderns invändiga beklädnad).
Reproduction is authorised provided the source is acknowledged. the child’s height and weight) over 1.4 m2.
Reproduction is authorised provided the source is acknowledged. överstiger 1,4 m2.
Reproduction is authorised provided the source is acknowledged. the dose may be further increased to the maximum dose of 36 mg per day.
Reproduction is authorised provided the source is acknowledged. tredje veckan kan dosen ökas ytterligare till en maximal dos på 36 mg per dag.
Reproduction is authorised provided the source is acknowledged. the maximum number is 4.
Reproduction is authorised provided the source is acknowledged. skydd mot solen patienten behöver.
Reproduction is authorised provided the source is acknowledged. the number of applications can be increased to three or four times a day.
Reproduction is authorised provided the source is acknowledged. gånger dagligen.
Reproduction is authorised provided the source is acknowledged. the ovaries (such as a follicle stimulating hormone [FSH] or human menopausal gonadotrophin [hMG] preparation).
Reproduction is authorised provided the source is acknowledged. behandling för att stimulera äggstockarna (t.ex. med ett preparat som innehåller follikelstimulerande hormon [FSH] eller humant menopausalt gonadotropin [hMG]).
Reproduction is authorised provided the source is acknowledged. the patient responds to treatment and, in the case of children, on the body surface area.
Reproduction is authorised provided the source is acknowledged. behandlingen samt, när det gäller barn, på kroppsytan.
Reproduction is authorised provided the source is acknowledged. the solution should be given by infusion (drip) into a vein over 15 minutes at a dose of 20 micrograms per kilogram body weight.
Till barn ges lösningen som en infusion (dropp) i en ven under 15 minuter, med en dos på 20 mikrogram per kilogram kroppsvikt.
Reproduction is authorised provided the source is acknowledged. the stomach.
Reproduction is authorised provided the source is acknowledged. pumpar in syra i magsäcken.
Reproduction is authorised provided the source is acknowledged. the type and stage of the disease being treated.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. the vaccine’s effect.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. therefore allowing the blood vessels to widen.
Reproduction is authorised provided the source is acknowledged. hormonets effekt, vilket gör det möjligt för blodkärlen att vidgas.
Reproduction is authorised provided the source is acknowledged. tissues where the cancer has spread, and the alpha particles destroy surrounding cancer cells and help to control the associated symptoms.
Reproduction is authorised provided the source is acknowledged. benvävnader dit cancern har spridit sig, och alfapartiklarna förstör omgivande cancerceller och hjälper till att reglera de förknippade symtomen.
Reproduction is authorised provided the source is acknowledged. together with the first daily dose of the levodopa preparation, and subsequent doses of Tasmar should be given approximately 6 and 12 hours later.
Reproduction is authorised provided the source is acknowledged. tillsammans med den första dagliga dosen av levodopaberedningen, och de följande två doserna av Tasmar ska tas omkring sex och tolv timmar senare.
Reproduction is authorised provided the source is acknowledged. tolerates the treatment.
Reproduction is authorised provided the source is acknowledged. behandlingen.
Reproduction is authorised provided the source is acknowledged. toxin, the immune system will be able to make antibodies against it more quickly.
Reproduction is authorised provided the source is acknowledged. oförändrade toxinet kommer immunsystemet att mycket snabbare kunna bilda antikroppar mot det.
Reproduction is authorised provided the source is acknowledged. treatment for as long as the doctor believes the patient is benefiting from it.
Reproduction is authorised provided the source is acknowledged. behandlingen.
Reproduction is authorised provided the source is acknowledged. treatment of both asthma and COPD, while Revinty Ellipta 184/22 microgram (184 micrograms of fluticasone furoate and 22 micrograms of vilanterol) can only be used for the treatment of asthma.
Reproduction is authorised provided the source is acknowledged. medan Revinty Ellipta 184/22 mikrogram (184 mikrogram flutikasonfuroat och 22 mikrogram vilanterol) bara kan användas för behandlingen av astma.
Reproduction is authorised provided the source is acknowledged. treatment with Axura should be reassessed on a regular basis.
Reproduction is authorised provided the source is acknowledged. inom tre månader efter att behandlingen påbörjas och sedan ska nyttan av fortsatt behandling med Axura bedömas regelbundet.
Reproduction is authorised provided the source is acknowledged. treatment with Ebixa should be reassessed on a regular basis.
Reproduction is authorised provided the source is acknowledged. bedömas inom 3 månader efter att behandlingen påbörjas och sedan ska nyttan av fortsatt behandling med Ebixa bedömas regelbundet.
Reproduction is authorised provided the source is acknowledged. vaccinated dogs since the vaccine does not prevent Leishmania infection.
Reproduction is authorised provided the source is acknowledged. efter vaccinationen och varar i ett år.
Reproduction is authorised provided the source is acknowledged. virus.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. week break without treatment and then a further two weeks of treatment.
Reproduction is authorised provided the source is acknowledged. på två veckor utan behandling och sedan behandling i ytterligare två veckor.
Reproduction is authorised provided the source is acknowledged. weekly injections followed by monthly maintenance injections.
Reproduction is authorised provided the source is acknowledged. gång i månaden.
Reproduction is authorised provided the source is acknowledged. weight is given by infusion into a vein every twelve hours, up to a maximum dose of 50 mg every 12 hours.
För barn som är 8–12 år ges en dos på 1,2 mg per kilogram kroppsvikt som en infusion i en ven var tolfte timme, upp till en maxdos på 50 mg var tolfte timme.
Reproduction is authorised provided the source is acknowledged. which results in uncontrolled activity of the central nervous system and death of these parasites.
Reproduction is authorised provided the source is acknowledged. dör.
Reproduction is authorised provided the source is acknowledged. work in similar ways to reduce blood pressure by allowing the blood vessels to relax.
Reproduction is authorised provided the source is acknowledged. och sänker blodtrycket genom att de får blodkärlen att slappna av.
Reproduction is authorised provided the source is acknowledged. worse or side effects become unacceptable.
Reproduction is authorised provided the source is acknowledged. blir oacceptabla.
Reproduction studies have been conducted in Cynomolgus monkeys at doses up to 25 times that of the weekly human maintenance dose of 2 mg/kg Herceptin intravenous formulation and have revealed no evidence of impaired fertility or harm to the fetus.
Reproduktionsstudier på Cynomolgusapor med doser upp till 25 gånger den veckovisa humana underhållsdosen på 2 mg/kg Herceptin intravenös beredning har inte visat belägg för minskad fertilitet eller fosterskada.
Reproduction studies in the rat and the rabbit showed no effect of agomelatine on fertility (see section 5.3).
Reproduktionsstudier på råtta och kanin visade ingen effekt av agomelatin på fertilitet (se avsnitt 5.3).
Reproduction toxicity studies with travoprost have been undertaken in rat, mice and rabbit by systemic route.
Reproduktionstoxikologiska studier med travoprost har företagits på råtta, mus och kanin med systemtillförsel.
Reproduction: sexual dysfunction, decreased libido, male sexual difficulty.
Fortplantning: Sexuell dysfunktion, minskad libido, sexsvårigheter hos män.
Reproduction:sexual dysfunction, decreased libido.
Reproduktionsorganen: Nedsatt sexuell förmåga, minskad sexuell lust.
Reproductive
Allmänna
Reproductive
Reproduktionsorgan och bröstkörtel
Reproductive and breast disorders
Reproduktionsorgan och bröstkörtel
Reproductive performance in rats given glycopyrronium shows a decrease in the rate of conception and in survival rate at weaning.
Reproduktionsförmåga hos råttor som får glykopyrronium uppvisar en sänkning av dräktighetsprocenten och i överlevnadstalen vid avvänjning.
Reproductive studies have been performed in pregnant cynomolgus monkeys receiving belimumab 150 mg/kg by intravenous infusion (approximately 9 times the anticipated maximum human clinical exposure) every 2 weeks for up to 21 weeks, and Benlysta treatment was not associated with direct or indirect harmful effects with respect to maternal toxicity, developmental toxicity, or teratogenicity.
Reproduktionsstudier har utförts på dräktiga cynomolgusapor som erhöll belimumab 150 mg/kg med intravenös infusion (cirka 9 gånger den förväntade maximala humana kliniska exponeringen) varannan vecka i upp till 21 veckor och behandling med Benlysta förknippades inte med direkta eller indirekta skadliga effekter med hänsyn till maternell toxicitet, utvecklingstoxicitet eller teratogenicitet.
Reproductive studies in animals have shown no effect on male or female fertility (see section 5.3).
Reproduktionsstudier på djur har inte visat någon effekt på manlig eller kvinnlig fertilitet (se avsnitt 5.3).
Reproductive system
Reproduktionssystemet:
Reproductive system and
Reproduktionsorgan och
Reproductive system and breast
Reproduktions- organ och bröst- körtel
Reproductive system and breast
Reproduktionsorgan och bröstkörtel
Reproductive system and breast disorder
Graviditet, puerperium och perinatalperiod
Reproductive system and breast disorder
Reproduktions- organ och bröstkörtel
Reproductive system and breast disorders
Allmänna symptom och /eller symptom vid administreringsstället
Reproductive system and breast disorders
Centrala och perifera nervsystemet
Reproductive system and breast disorders
Hud och subkutan vävnad
Reproductive system and breast disorders
klassificering av organsystem (SOC)
Reproductive system and breast disorders
Muskuloskeletala systemet och bindväv
Reproductive system and breast disorders
n och bröstkörtel
Reproductive system and breast disorders
Organsystemklassifice ring
Reproductive system and breast disorders
Reproduktions organ och bröst körtel
Reproductive system and breast disorders
Reproduktions- organ och bröst- körtel
Reproductive system and breast disorders
Reproduktions- organ och bröstkörtel
Reproductive system and breast disorders
Reproduktionsorgan
Reproductive system and breast disorders
Reproduktionssystem och bröstkörtel
Reproductive system and breast disorders
Systemorganklass Biverkningar Reproduktionsorgan och bröstkörtel
Reproductive system and breast disorders uncommon: dysmenorrhoea and uterine bleeding
Reproduktionsorgan och bröstkörtel mindre vanliga: dysmenorré och livmoderblödningar
Reproductive system and breast Uncommon: sexual dysfunction, libido changes  disorders:
Reproduktionsorgan och Mindre vanliga: sexuell dysfunktion, förändring av libido  bröstkörtel:
Reproductive system bleedingsk
Blödningar i reproduktionssystemk
Reproductive system disorders: Impotence (inability to maintain an erection)
Reproduktionsorgan: Impotens (oförmåga att bibehålla erektion)
Reproductive system, and breast disorders
Reproduktionsorgan och bröstkörtel
Reproductive systems and breast disorders
Reproduktions- organ och bröstkörtel
Reproductive toxicity and impairment of fertility studies with CE/bazedoxifene have not been conducted.
Inga studier avseende reproduktionstoxicitet och nedsatt fertilitet med CE/bazedoxifen har utförts.
Reproductive toxicity studies have not been conducted with blinatumomab.
Reproduktionsstudier har inte utförts med blinatumomab.
Reproductive toxicity studies have not been conducted with blinatumomab.
Reproduktionstoxiska studier har inte utförts med blinatumomab.
Reproductive toxicity studies in rats and rabbits showed no effects on mating, fertility, pregnancy or fetal parameters.
Reproduktionstoxicitetsstudier på råtta och kanin visade inga effekter på parnings-, fertilitets-, dräktighets- eller fosterparametrar.
Reproductive toxicity studies in rats and rabbits showed no effects on mating, fertility, pregnancy or fetal parameters.
Reproduktionstoxicitetsstudier på råttor och kaniner visade inga effekter på parnings-, fertilitets-, dräktighets- eller fosterparametrar.
Reproductive toxicity studies in rats and rabbits with cobicistat showed no effects on mating, fertility, pregnancy or fetal parameters.
Reproduktionstoxikologiska studier på råtta och kanin med kobicistat visade inga effekter på parning, fertilitet, dräktighet eller fosterparametrar.
Reproductive toxicity studies with fesoterodine in animals show minor embryotoxicity (see section 5.3).
Reproduktionstoxikolgiska studier med festoterodin på djur visar på begränsad embryotoxicitet (se avsnitt 5.3).
Reproductive toxicity testing showed no evidence of effects on fertility, embryofetal, or postnatal development.
Reproduktionstoxikologiska prov visade inga tecken på effekter på fertilitet, embryonal-/foster- utveckling eller postnatal utveckling.
Reproductive toxicity was shown in a study of cynomolgus monkeys, dosed throughout pregnancy with denosumab at AUC exposures 119-fold higher than the human dose (see section 5.3).
Reproduktionstoxicitet påvisades i en studie på cynomolgusapor som under hela dräktigheten gavs denosumab i doser som resulterade i 119 gånger högre AUC-exponering än dosen till människa (se avsnitt 5.3).
Reproductive toxicity was shown in a study of cynomolgus monkeys, dosed throughout pregnancy with denosumab at AUC exposures 12-fold higher than the human dose (see section 5.3).
Reproduktionstoxicitet påvisades i en studie på cynomolgusapor som under hela dräktigheten gavs denosumab i doser som resulterade i 12 gånger högre AUC-exponering än dosen till människa (se avsnitt 5.3).
Reproductive toxicology studies (i.e. embryo-foetal development studies) in pregnant rats and rabbits indicated no foetotoxicity or teratogenicity after dosing with ceritinib during organogenesis; however, maternal plasma exposure was less than that observed at the recommended dose of 750 mg in clinical trials.
Reproduktionstoxikologiska studier (dvs. studier av embryofetal utveckling) hos dräktiga råttor och kaniner visade inte på någon fostertoxicitet eller teratogenicitet efter dosering av ceritinib under organogenesen, dock var plasmaexponeringen hos moderdjuret lägre än den som observerats i kliniska prövningar med den rekommenderade dosen 750 mg.
reproductive tract infections
infektioner i reproduktionsorganen
reproductive tract infections (including vulvovaginal mycotic infection),
Lymfom**, solid organneoplasm (inklusive
reproductive tract infections;
infektioner i reproduktionsorganen;